Goldman Sachs Increases Stake in Evotec SE to 14.62%
EVO sits 21% above its 52-week low of $2.308 on light trading volume (0.3× avg).
Summary
Goldman Sachs has increased its total stake in Evotec SE to 14.62%, indicating a stronger position in the company.
Key Events · Ownership and Investor Activity · EVO
-
Goldman Sachs Increases Total Stake
The Goldman Sachs Group, Inc. reported an increase in its total voting rights in Evotec SE from 12.42% to 14.62%, crossing the threshold on June 23, 2026.
-
Exposure Primarily Through Instruments
The 2.20 percentage point increase was largely driven by an accumulation of derivative instruments, including rights to recall, rights of use, convertible bonds, swaps, and call warrants.
-
Strategic Positioning Amidst Recent Events
This increased institutional exposure follows Evotec's recent convertible bond placement and comes amidst a period of financial challenges and activist investor involvement.
Analysis · EVO · Life Sciences
The Goldman Sachs Group, Inc. has significantly increased its total voting rights in Evotec SE from 12.42% to 14.62%, primarily through derivative instruments. This increased exposure by a major institutional investor suggests a strategic interest or a vote of confidence in the company, especially following recent financial challenges and a convertible bond issuance.
At the time of this filing, EVO was trading at $2.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.31 to $4.42. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.